8,184 Shares in RadNet, Inc. (NASDAQ:RDNT) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new stake in shares of RadNet, Inc. (NASDAQ:RDNT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,184 shares of the medical research company's stock, valued at approximately $572,000.

Several other large investors also recently added to or reduced their stakes in the business. USA Financial Formulas purchased a new stake in shares of RadNet in the fourth quarter valued at approximately $30,000. Fifth Third Bancorp boosted its stake in shares of RadNet by 84.3% during the fourth quarter. Fifth Third Bancorp now owns 667 shares of the medical research company's stock worth $47,000 after buying an additional 305 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of RadNet by 377.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,345 shares of the medical research company's stock worth $96,000 after buying an additional 1,063 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of RadNet by 42.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,422 shares of the medical research company's stock worth $99,000 after acquiring an additional 422 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of RadNet during the 4th quarter worth approximately $105,000. 77.90% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Cornelis Wesdorp sold 2,000 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $52.58, for a total transaction of $105,160.00. Following the completion of the sale, the chief executive officer now owns 58,995 shares of the company's stock, valued at $3,101,957.10. This represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David L. Swartz sold 25,000 shares of RadNet stock in a transaction on Friday, March 7th. The shares were sold at an average price of $50.84, for a total value of $1,271,000.00. Following the transaction, the director now owns 174,067 shares in the company, valued at approximately $8,849,566.28. This trade represents a 12.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,000 shares of company stock valued at $1,926,730. 5.12% of the stock is currently owned by company insiders.

RadNet Stock Performance

Shares of NASDAQ RDNT traded up $0.17 during trading on Tuesday, hitting $53.30. The company had a trading volume of 632,472 shares, compared to its average volume of 664,694. RadNet, Inc. has a 12 month low of $45.00 and a 12 month high of $93.65. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.16 and a current ratio of 2.16. The firm has a market capitalization of $4.00 billion, a P/E ratio of -761.32 and a beta of 1.46. The stock has a 50 day simple moving average of $50.68 and a 200 day simple moving average of $63.70.

RadNet (NASDAQ:RDNT - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.01. The company had revenue of $477.10 million during the quarter, compared to analysts' expectations of $459.42 million. RadNet had a negative net margin of 0.25% and a positive return on equity of 4.29%. As a group, analysts anticipate that RadNet, Inc. will post 0.56 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on RDNT. Raymond James upgraded RadNet from an "outperform" rating to a "strong-buy" rating and dropped their price objective for the stock from $85.00 to $65.00 in a report on Wednesday, March 5th. Jefferies Financial Group cut their price objective on RadNet from $100.00 to $80.00 and set a "buy" rating for the company in a research report on Wednesday, January 15th. Truist Financial dropped their target price on shares of RadNet from $88.00 to $74.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Barclays reduced their price target on RadNet from $74.00 to $60.00 and set an "overweight" rating on the stock in a research report on Monday, March 24th. Finally, StockNews.com raised shares of RadNet to a "sell" rating in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $69.75.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.